Research programme: anti-galectin 9 monoclonal antibodies - FibroGen/HiFiBiO
Alternative Names: Anti-Gal-9 monoclonal antibodies - HiFiBiO TherapeuticsLatest Information Update: 28 Jun 2024
At a glance
- Originator HiFiBiO
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Galectin inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 17 Jun 2021 Fibrogen in-licenses anti-galectin 9 monoclonal antibodies from HiFiBio worldwide
- 17 Jun 2021 Fibrogen and HiFiBio plans clinical trial for an anti-galectin 9 monoclonal antibody in Cancer (Parenteral) in the first quarter of 2023